Biotech entity

PharmaTrac

Product

pharma is the sole category represented across all 1 tracked stories. PharmaTrac is most often covered alongside Anti-Diabetic Segment, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. PharmaTrac appears in 1 tracked Biotech story from August 9, 2026.

Last mentioned: Aug 9, 2026

RSS updates

Entity pulse

Recent coverage · PharmaTrac

1 story

avg impact

0% positive

0% negative

100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about PharmaTrac

Stories tracked: 1
Sources per story: 2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering PharmaTrac. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning PharmaTrac 1

Pharma Neutral

Oncology, diabetes drive Indian pharma; Mounjaro sales up 880% to ₹1,228 Cr

The Indian pharmaceutical market expanded 12.1% by value in July 2026, but unit growth inched up only 1.6%, revealing a market shifting to high-value, specialty therapies. Anti-neoplastics and anti-diabetics led therapy-area growth, while Eli Lilly’s Mounjaro captured more than half of the diabetes segment with an 880% sales surge. For biotech and pharma firms, the data underscores the imperative to invest in innovation and patient access strategies.

Aug 9, 2026 2 sources

Source: aninews.in · bignewsnetwork.com

PharmaTrac is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.